247: Vertex vs. insurers, Moderna's future, & biotech's long winter
STAT’s Ed Silverman joins us to explain how an escalating fight between Vertex Pharmaceuticals and insurance companies has left patients and families caught in the middle. We also discuss the latest n...
23 Feb 202338min
246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid
Vas Narasimhan, CEO of Novartis and the new chairman of PhRMA, joins us to discuss the industry’s struggles in Washington and whether the deflated biotech sector is still overvalued. We also dive into...
16 Feb 202340min
245: The return of bird flu and the effects of pandemic fatigue
Helen Branswell, STAT’s senior writer covering infectious disease, joins us to explain the sudden resurgence of a bird flu virus called H5N1 and why experts are watching the situation closely.
9 Feb 202320min
244: Pharma blockbusters, pandemic policy, & legal chicanery
STAT Washington correspondent Rachel Cohrs joins us to explain the looming end of Covid-19's status as a federal emergency and what that does and doesn't mean for public health. We also dig into the m...
2 Feb 202335min
243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection
George Scangos, the CEO of Vir Biotechnology, joins us to discuss his retirement and offer some perspective and lessons from a remarkable, 40-year career in biotech. We also chat about the latest news...
26 Jan 202331min
242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score
Journalist Nathan Vardi joins us to talk about his new book delving into the race to develop the lifesaving cancer drug now called Imbruvica, involving a Scientologist CEO and secretive investor seeki...
19 Jan 202332min
241: #JPM23 in review, the year ahead, & the merits of Miami
With the 2023 J.P. Morgan Healthcare Conference drawing to a close, we look back on the biggest news of the meeting, what it means for the year in biotech ahead, and whether the industry's biggest ann...
12 Jan 202332min
240: #JPM23, the future of Alzheimer's, & rising Covid variants
First, we delve into a sweeping congressional investigation into the FDA's approval of the last treatment for Alzheimer's disease and what it means for the next one. We also preview the upcoming J.P. ...
5 Jan 202336min
